NAME Prof. Michelle Haber
CANCER TYPE Leukaemia
INSTITUTION University of NSW, Children's Cancer Institute of Australia
STATE New South Wales
GRANT TYPE $200,000
PROJECT TYPE Research
"A promising new drug, CBL0137, blocks cancer cell growth by inhibiting the cancer‐associated protein, FACT. Leukaemia in infants is normally very hard to treat, despite intensive regimens... However this new agent potently kills infant leukaemia cells and we propose to develop CBL0137 for clinical use in children with aggressive leukaemia."
Professor Michelle Haber, Leukaemia researcher for UNSW and the Children's Cancer Institute